Uroplasty (UPI) Earns News Impact Rating of 0.09

News stories about Uroplasty (NASDAQ:UPI) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Uroplasty earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 44.748328108087 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Uroplasty (UPI) opened at $1.22 on Monday. Uroplasty has a twelve month low of $1.05 and a twelve month high of $4.05. The stock has a market cap of $27.68, a PE ratio of -4.07 and a beta of -1.26.

ILLEGAL ACTIVITY NOTICE: “Uroplasty (UPI) Earns News Impact Rating of 0.09” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/02/19/uroplasty-upi-earns-daily-media-impact-score-of-0-09.html.

Uroplasty Company Profile

Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.

Insider Buying and Selling by Quarter for Uroplasty (NASDAQ:UPI)

Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply